Filing Analysis
Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for Telomir-Zn in the journal Biomedicine & Pharmacotherapy. The study demonstrated dose-dependent improvements in glucose homeostasis and insulin resistance using a zebrafish model of Type 2 diabetes.
📋 Key Facts
- Publication title: 'Telomir-Zn Restores Glucose Homeostasis and Reduces Insulin Resistance in a Diet-Induced Zebrafish Model of Type 2 Diabetes'
- Study showed improvements in fasting blood glucose, glucose tolerance, fasting insulin levels, and HOMA-IR
- This is the company's second peer-reviewed publication in 2026
- Telomir-Zn has already received FDA IND clearance for Phase 1/2 clinical trials (TELO-001) for advanced or metastatic triple-negative breast cancer
Telomir Pharmaceuticals announced the departure of CFO Alan Weichselbaum and the appointment of Andriy Mushak as Fractional CFO effective June 6, 2026. Mr. Mushak is a partner at LMAM Consulting Group, LLC, and will provide services via a consulting agreement.
🚩 Red Flags
- Transition from a full-time CFO to a 'Fractional' CFO may indicate budget constraints or a lack of stability in the financial leadership role.
📋 Key Facts
- Alan Weichselbaum ceased serving as CFO effective June 6, 2026.
- Andriy Mushak appointed as Fractional CFO effective June 6, 2026.
- Mr. Mushak is a CPA and Partner at LMAM Consulting Group, LLC.
- The Company will pay Mr. Mushak $6,000 per month for his services under a Consulting Agreement with LMAM.
- The departure of Mr. Weichselbaum was not due to any disagreement with the Company.
Telomir Pharmaceuticals announced the publication of a peer-reviewed preclinical study on its compound Telomir-1 (Telomir-Zn) in the journal Advances in Redox Research. The study demonstrated positive therapeutic effects of Telomir-1 in cellular systems and a zebrafish model of Wilson's disease.
📋 Key Facts
- Published a peer-reviewed preclinical study on Telomir-1 in the journal Advances in Redox Research on May 20, 2026.
- The study evaluated Telomir-1 (Telomir-Zn) in cellular systems and an ATP7B-deficient zebrafish model of Wilson's disease.
- Findings showed reductions in oxidative stress signaling, hepatic copper accumulation, liver injury biomarkers, and improvements in survival outcomes.
Telomir Pharmaceuticals received FDA clearance for its Investigational New Drug (IND) application for Telomir-Zn to treat triple-negative breast cancer. The company plans to initiate a Phase 1/2 clinical trial in the first half of 2026.
📋 Key Facts
- FDA cleared the IND application for lead product candidate Telomir-Zn on April 24, 2026.
- The target indication is advanced or metastatic triple-negative breast cancer (TNBC).
- The planned Phase 1/2 trial will enroll approximately 76 patients.
- The trial will be conducted at a leading U.S. academic medical center.
- Primary endpoint for the Phase 2 portion is Objective Response Rate (ORR).
Telomir Pharmaceuticals completed the acquisition of TELI Pharmaceuticals to consolidate global rights for its lead drug candidate, Telomir-1. The transaction involved the issuance of over 34 million restricted shares and includes a $1 million immediate cash contribution from Bayshore Trust.
🚩 Red Flags
- Massive equity dilution: The issuance of 34,389,710 shares is likely a very large percentage of the total shares outstanding for a micro-cap company.
- Valuation risk: The exchange ratio was based on third-party valuations of private and public entities, which can be highly subjective in early-stage biotech.
- Concentration of control: Significant share issuance to a specific group (TELI shareholders) and the involvement of Bayshore Trust.
📋 Key Facts
- Acquisition of 100% of TELI Pharmaceuticals completed on April 22, 2026.
- Issued 34,389,710 restricted shares of common stock as consideration to TELI shareholders.
- Consolidates global rights for Telomir-1 (Telomir-Zn), eliminating previous geographic fragmentation between North American and international markets.
- Bayshore Trust contributed $1 million in cash at closing as a condition of the deal.
- Bayshore Trust entered a Commitment Agreement to potentially pay up to $4 million more upon FDA IND acceptance and Phase 1/2 clinical study initiation.
Telomir Pharmaceuticals, Inc. has regained compliance with Nasdaq Listing Rule 5620(a) following the completion of its 2025 Annual Meeting of Shareholders. Nasdaq has officially closed the matter, resolving the previous deficiency regarding shareholder meeting requirements.
🚩 Red Flags
- The company was previously non-compliant with Nasdaq rules, indicating a past failure to meet basic corporate governance requirements (holding an annual meeting).
📋 Key Facts
- Received a compliance letter from Nasdaq Capital Markets on March 30, 2026.
- The company is now in compliance with Nasdaq Listing Rule 5620(a).
- Compliance was achieved by holding the 2025 Annual Meeting of Shareholders.
- Nasdaq has determined the matter is now closed and the company remains listed on The Nasdaq Stock Market LLC.
Telomir Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for Telomir-1 (Telomir-Zn) to treat advanced and metastatic Triple-Negative Breast Cancer (TNBC). The company plans to initiate a Phase 1/2 clinical trial evaluating the drug as an oral monotherapy upon FDA clearance.
📋 Key Facts
- IND application submitted to the FDA on March 31, 2026.
- Target indication is advanced and metastatic Triple-Negative Breast Cancer (TNBC).
- Telomir-1 (Telomir-Zn) is a small-molecule epigenetic therapy targeting iron-dependent pathways.
- Planned Phase 1/2 trial will use a 3+3 dose-escalation design followed by a Simon two-stage design for Phase 2.
- Preclinical GLP safety studies reported no treatment-related adverse or dose-limiting toxicities.
- The company intends to present data at the AACR Annual Meeting 2026.
Telomir Pharmaceuticals received shareholder approval for the acquisition of Teli Pharmaceuticals and a significant expansion of its equity incentive plan. The company also amended its bylaws to reduce the quorum requirement for shareholder meetings to one-third and authorized the repricing of underwater stock options.
🚩 Red Flags
- Significant potential dilution from the 5,000,000 share increase in the incentive plan (approx. 14.5% of total outstanding shares).
- The introduction of option repricing allows management to lower exercise prices if the stock price drops, which is often viewed as shareholder-unfriendly.
- Reducing the quorum requirement to one-third makes it easier for a minority of shareholders to pass significant corporate actions.
- The acquisition of Teli Pharmaceuticals involves a share issuance exceeding 20% of the current outstanding stock.
📋 Key Facts
- Shareholders approved the acquisition of Teli Pharmaceuticals, Inc., involving the issuance of more than 20% of outstanding common stock.
- The 2023 Omnibus Incentive Plan was amended to increase reserved shares from 6,500,000 to 11,500,000.
- The amended Incentive Plan now allows for the repricing of options or stock appreciation rights (SARs) at the administrator's discretion.
- Bylaws were amended to reduce the quorum requirement for shareholder actions to one-third (33.3%).
- As of the January 23, 2026 record date, there were 34,380,971 shares of common stock outstanding.
- Salberg & Company, P.A. was ratified as the independent auditor for the fiscal year ending December 31, 2025.